Trans1 (TSON)

medical device company. Purchased TSON today @6.54/share in real life portfolio.

outperform. company is HIGH in cash. not terribly overvalued, and is likely to kill S&P 500 where it is at today's levels.
additionally these companies are not within the financials nor energy sectors.

Technology is extremely different from alternative approaches to spinal fusion in the lumbar spine, recovery is un-heard of, procedure is done in 45-1hr...and patients do very well...sometimes go home in the same day...ask any neuro or ortho spine doctor what spinal fusion technique can do that.

This stock is in the healthcare sector of the market and the industry of medical equipment and supplies industry. It's revenues for last year 2007 totaled $16.5M and the net income fell 10% which refllects an increase in number of products sold resulted from the continued market acceptance of the Axialif products.